|Mr. Donald J. McCaffrey||Co-Founder, Chairman Pres, CEO & Sec.||N/A||N/A||N/A|
|Mr. Aaron Bradley Cann CA, CPA, CBV||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Kenneth Eugene Lebioda BA||Sr. VP of Bus. & Corp. Devel.||N/A||N/A||N/A|
|Dr. Jan O. Johansson||Sr. VP of Medical Affairs||N/A||N/A||N/A|
|Dr. Michael Sweeney||Sr. VP of Clinical Devel.||N/A||N/A||1961|
Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.